Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
India
/
Pharmaceuticals & Biotech
/
Strides Pharma Science
Create a narrative
Strides Pharma Science Community
NSEI:STAR Community
3
Narratives
written by author
0
Comments
on narratives written by author
9
Fair Values set
on narratives written by author
Community Investing Ideas
Strides Pharma Science
Popular
Undervalued
Overvalued
Strides Pharma Science
AN
AnalystHighTarget
Community Contributor
Aging Populations And Emerging Markets Will Energize Generic Demand
Key Takeaways Strides is achieving stronger margins and growth than expected, driven by portfolio rationalization, operational enhancements, and effective entry into less competitive, higher-margin products. Expansion into differentiated products and emerging markets is reducing risk and supporting sustainable, stable revenue and earnings growth.
View narrative
₹1.22k
FV
31.2% undervalued
intrinsic discount
14.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
15 days ago
author updated this narrative
Strides Pharma Science
AN
AnalystConsensusTarget
Based on Analyst Price Targets
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
Key Takeaways Expansion in high-value generics, R&D investments, and digital transformation are driving diversified growth and long-term profitability across regulated and emerging markets. Streamlined product portfolio, cost optimization, and supply chain efficiencies are boosting margins and supporting sustainable earnings improvement.
View narrative
₹1.08k
FV
22.2% undervalued
intrinsic discount
12.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
21 days ago
author updated this narrative
Strides Pharma Science
AN
AnalystLowTarget
Community Contributor
US Market Dependency Will Strain Margins Yet Yield Opportunity
Key Takeaways Heavy reliance on the US market and supply chain risks could create earnings volatility and slow global expansion efforts. Intensifying competition, regulatory pressures, and shifting pharmaceutical trends may limit further margin gains and long-term growth potential.
View narrative
₹937
FV
10.4% undervalued
intrinsic discount
13.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
22 days ago
author updated this narrative